Lipid-based nanosystems have emerged as a promising platform for cancer immunotherapy, offering enhanced delivery, targeting, and modulation of immune responses. These systems, including liposomes, lipid nanoparticles (LNPs), solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and hybrid lipid nanoparticles, have shown significant potential in improving the efficacy and safety of immunotherapies. They enable the targeted delivery of immunomodulatory agents, such as antibodies, nucleic acids, and small molecules, to cancer cells while minimizing off-target effects. Lipid-based NPs can also modulate the immune system directly, enhance the accumulation of therapeutic agents in the tumor microenvironment (TME), and overcome challenges such as poor solubility, low bioavailability, and systemic toxicity. Key advantages of lipid-based nanosystems include their ability to enhance drug delivery, improve pharmacokinetics, and enable passive and active targeting of tumors. They can also be engineered to respond to specific stimuli, such as pH, redox, or enzymatic changes, allowing for controlled release of therapeutic agents. Additionally, lipid-based NPs can be functionalized with immune-modulating components, such as adjuvant lipids, to enhance immune responses and overcome immunosuppressive signals in the TME. These systems have been successfully used in various immunotherapeutic applications, including immune checkpoint inhibition, adoptive cellular therapy, and cytokine delivery. Lipid-based NPs have shown promise in clinical trials for cancer immunotherapy, with several formulations currently under investigation. These include lipid-based vaccines, gene delivery systems, and combination therapies with other immunotherapies. For example, LNPs have been used to deliver mRNA vaccines against COVID-19, while lipid-based NPs have been tested for the delivery of immune checkpoint inhibitors and cytokines such as IL-12. These systems have demonstrated improved therapeutic outcomes, reduced toxicity, and enhanced tumor targeting. In addition to their role in drug delivery, lipid-based NPs can be used to engineer T cells, enhance their function, and enable their targeted delivery to tumors. They have also been used to deliver cytokines such as IL-2, IL-12, and IL-15, which can stimulate T cell activity and enhance immune responses. Furthermore, lipid-based NPs can be functionalized to target specific cell types within the TME, such as tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), to modulate the immunosuppressive environment and improve treatment outcomes. Overall, lipid-based nanosystems represent a significant advancement in cancer immunotherapy, offering a versatile platform for targeted delivery, immune modulation, and enhanced therapeutic efficacy. As research continues to explore the potential of these systems, they are expected to play a crucial role in the next generation of immunotherapies, improving the precision and effectiveness of cancer treatment.Lipid-based nanosystems have emerged as a promising platform for cancer immunotherapy, offering enhanced delivery, targeting, and modulation of immune responses. These systems, including liposomes, lipid nanoparticles (LNPs), solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and hybrid lipid nanoparticles, have shown significant potential in improving the efficacy and safety of immunotherapies. They enable the targeted delivery of immunomodulatory agents, such as antibodies, nucleic acids, and small molecules, to cancer cells while minimizing off-target effects. Lipid-based NPs can also modulate the immune system directly, enhance the accumulation of therapeutic agents in the tumor microenvironment (TME), and overcome challenges such as poor solubility, low bioavailability, and systemic toxicity. Key advantages of lipid-based nanosystems include their ability to enhance drug delivery, improve pharmacokinetics, and enable passive and active targeting of tumors. They can also be engineered to respond to specific stimuli, such as pH, redox, or enzymatic changes, allowing for controlled release of therapeutic agents. Additionally, lipid-based NPs can be functionalized with immune-modulating components, such as adjuvant lipids, to enhance immune responses and overcome immunosuppressive signals in the TME. These systems have been successfully used in various immunotherapeutic applications, including immune checkpoint inhibition, adoptive cellular therapy, and cytokine delivery. Lipid-based NPs have shown promise in clinical trials for cancer immunotherapy, with several formulations currently under investigation. These include lipid-based vaccines, gene delivery systems, and combination therapies with other immunotherapies. For example, LNPs have been used to deliver mRNA vaccines against COVID-19, while lipid-based NPs have been tested for the delivery of immune checkpoint inhibitors and cytokines such as IL-12. These systems have demonstrated improved therapeutic outcomes, reduced toxicity, and enhanced tumor targeting. In addition to their role in drug delivery, lipid-based NPs can be used to engineer T cells, enhance their function, and enable their targeted delivery to tumors. They have also been used to deliver cytokines such as IL-2, IL-12, and IL-15, which can stimulate T cell activity and enhance immune responses. Furthermore, lipid-based NPs can be functionalized to target specific cell types within the TME, such as tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), to modulate the immunosuppressive environment and improve treatment outcomes. Overall, lipid-based nanosystems represent a significant advancement in cancer immunotherapy, offering a versatile platform for targeted delivery, immune modulation, and enhanced therapeutic efficacy. As research continues to explore the potential of these systems, they are expected to play a crucial role in the next generation of immunotherapies, improving the precision and effectiveness of cancer treatment.